Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bivariate sequential designs for phase II trials

M R Conaway1, G R Petroni

  • 1Duke University Medical Center, Durham, North Carolina 27710, USA.

Biometrics
|June 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Screening Echocardiography Identifies Risk Factors for Pulmonary Hypertension at Discharge in Premature Infants with Bronchopulmonary Dysplasia.

Pediatric cardiology·2022
Same author

A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

Gynecologic oncology·2020
Same author

Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Recent developments in the implementation of novel designs for early-phase combination studies.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Factors related to decision making and substance use in adolescent survivors of childhood cancer: a presenting clinical profile.

Journal of cancer survivorship : research and practice·2013
Same author

Postoperative chylothorax development is associated with increased incidence and risk profile for central venous thromboses.

Pediatric cardiology·2007
Same journal

Fast penalized generalized estimating equations for large longitudinal functional datasets.

Biometrics·2026
Same journal

Causally-interpretable random-effects meta-analysis.

Biometrics·2026
Same journal

Statistical inference for mean function of partially observed functional time series.

Biometrics·2026
Same journal

Subgroup identification via Interaction Tree and Mixed Model for Repeated Measures with application to Alzheimer's disease.

Biometrics·2026
Same journal

Finite mixtures of linear quantile regressions with concomitant variables: a solution to endogeneity in longitudinal data modeling.

Biometrics·2026
Same journal

Discussion on "INTACT: a method for integration of longitudinal physical activity data from multiple sources" by Jingru Zhang, Erjia Cui, Hongzhe Li, and Haochang Shou.

Biometrics·2026
See all related articles

This study introduces new methods for group sequential phase II clinical trials with two linked binary outcomes. These methods help define stopping rules for trials needing few patients, focusing on antitumor activity and toxicity.

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Pharmacological Research

Background:

  • Phase II clinical trials are crucial for evaluating drug efficacy and safety.
  • Sequential trial designs allow for early stopping, conserving resources.
  • Managing multiple, dependent endpoints in early-phase trials presents statistical challenges.

Purpose of the Study:

  • To develop and present methods for designing group sequential phase II trials.
  • To derive precise stopping rules for trials with two dependent binary endpoints.
  • To facilitate efficient trial designs requiring a small patient cohort.

Main Methods:

  • Utilizing exact distributions of binary endpoints for precise calculations.
  • Enumerating discrete probability distributions for endpoint analysis.

Related Experiment Videos

  • Applying group sequential design principles to phase II trial monitoring.

    • Main Results:

    • The proposed methods provide a framework for deriving optimal stopping rules.
    • Demonstrated the applicability of the methods in a practical clinical scenario.
    • Enabled monitoring of both antitumor activity and toxicity within a small sample size.

    Conclusions:

    • The developed methods offer a statistically sound approach for group sequential phase II trials.
    • These techniques are particularly valuable when dealing with multiple, dependent binary endpoints.
    • The study highlights the importance of tailored statistical designs for efficient early-phase drug development.